Detalhe da pesquisa
1.
EGFR activation limits the response of liver cancer to lenvatinib.
Nature
; 595(7869): 730-734, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34290403
2.
Inducing and exploiting vulnerabilities for the treatment of liver cancer.
Nature
; 574(7777): 268-272, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31578521
3.
Cancer cell genetics shaping of the tumor microenvironment reveals myeloid cell-centric exploitable vulnerabilities in hepatocellular carcinoma.
Nat Commun
; 15(1): 2581, 2024 Mar 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38519484
4.
Ras/MAPK signalling intensity defines subclonal fitness in a mouse model of hepatocellular carcinoma.
Elife
; 122023 01 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-36656749
5.
Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma.
Mol Oncol
; 17(6): 964-980, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36650715
6.
Multiparametric Analyses of Hepatocellular Carcinoma Somatic Mouse Models and Their Associated Tumor Microenvironment.
Curr Protoc
; 1(6): e147, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-34101385
7.
Understanding the Origin and Diversity of Macrophages to Tailor Their Targeting in Solid Cancers.
Front Immunol
; 10: 2215, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31611871